MedTrace Logo

Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP

NCT06552741 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-04-08

No results posted yet for this study

Summary

Background:

People who will participate in research studies need to undergo proper screening, evaluation, and assessment (SEA). SEA helps keep those who participate in studies safe. It also helps ensure accurate study results. The National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) wants to screen people with alcohol and/or substance use disorders (ASUD) as well as people without ASUD for ongoing studies at NIDA in Baltimore, MD

Objective:

To screen people with or without ASUD for ongoing studies at NIDA. The ultimate goals are to learn why some people (1) use drugs; (2) stop using drugs; (3) use drugs but do not get addicted; and (4) never use drugs snd to develop ASUD treatments.

Eligibility:

People aged 18 years and older. They may (1) currently use nicotine, alcohol, opioids, cocaine, or other drugs; (2) no longer use them; or (3) have never used them.

Design:

Participants will have 1 screening visit that could last up to 8 hours. The visit may be split over more than 1 day. The duration of the screening may vary for each individual based on which studies they are interested in and screened for. The tests they undergo may vary and may include the following:

* Physical exam.
* Blood, saliva, and urine tests.
* Breath samples that test for alcohol and carbon monoxide.
* Test of heart function.
* Smell test that measures sense of smell.
* Tests of memory, attention, and thinking.
* Mental health evaluation.
* Mock magnetic resonance imaging (MRI) scan.
* Questionnaires about alcohol and other drug use, mental health, medical history, and life in general.

Conditions

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Lorenzo Leggio, M.D. · National Institute on Drug Abuse (NIDA)

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-04
Primary Completion
2045-01-01
Completion
2047-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06552741 on ClinicalTrials.gov